Previous clinical studies (19–26) have found that Tα1 has a beneficial immunomodulatory effect in patients with a variety of diseases, including malignant tumors, sepsis-induced lung injury, and COVID-19 (Table 1). Here, TAAR1 is linked to COVID-19.